SANTA FE, N.M., Nov. 14, 2013 /PRNewswire/ -- Sigma Labs, Inc. (OTCBB: SGLB) announced today that it has obtained the complete assignment interest in its critical patent on advanced dental implant technology thereby enabling commercialization to proceed unencumbered. This supports Sigma Labs exclusive marketing agreement (EMA) with Manhattan Scientifics, Inc. ( http://mhtx.com). The EMA sets forth the parties intent to market Sigma Labs technology to prospective licensees and strategic partners. The Sigma Labs rapid healing implant uses former U.S. National Laboratory technology to create a surface that can completely integrate with bone in four to six weeks, with attendent reduction of inflamation and patient discomfort.

Mark Cola, President and Chief Executive Officer of Sigma Labs, stated that, "In an continuing effort to monetize our full IP portfolio while maintaining focus on our efforts in PrintRite3D ® for metal 3D printing, we are pleased to work with Manhattan Scientifics to identify prospective licensees and strategic partners for our advanced dental implant technology. Manhattan Scientifics has a similar heritage of commercializing advanced technology from leading U.S. national research institutions."

Manny Tsoupanarias, Chief Executive Officer of Manhattan Scientifics further stated that, "We are pleased to have the opportunity to market Sigma Labs dental technology. We feel this technology may be very attractive to the global dental implant market and potentially other implants as well. We plan to leverage our previous work and contacts within the industry to create new opportunities for both of our companies." Manny Tsoupanarias continued that "Sigma Labs technology is entirely in line with our focus on nano-medicine technologies and augments our previous work in nanomaterials for dental implants."

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks, uncertainties and assumptions that could adversely affect us, including the risks set forth in our most recent annual report on Form 10-K. The forward-looking statements in this press release are made only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.

Mark Cola, President and CEO of Sigma Labs, Inc., +1-505-438-2576

SOURCE Sigma Labs, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.